Business context and reporting period
Castle Biosciences, Inc. filed its Form 10-K for the fiscal year ended December 31, 2019. The commercial-stage dermatological cancer company sells genomic tests that inform cancer risk and treatment decisions. Its principal products are DecisionDx-Melanoma and DecisionDx-UM; DecisionDx-SCC and a suspicious pigmented lesion test were in late-stage development. The company completed its IPO in July 2019.
Financial and operating performance
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $51.9 million | $22.8 million |
| Gross profit / margin | $44.6 million / 85.9% | $17.5 million / 76.8% |
| Operating income (loss) | $7.3 million | $(3.8) million |
| Net income (loss) | $5.3 million | $(6.4) million |
| Net cash from (used in) operating activities | $7.0 million | $(12.3) million |
| Cash and cash equivalents at year-end | $98.8 million | $4.5 million |
| Long-term debt carrying value | $25.1 million | $24.5 million |
Revenue rose 127.6%, driven primarily by DecisionDx-Melanoma volume and higher per-test revenue, including the test’s new ADLT Medicare status and the full-year effect of its Medicare coverage determination. Delivered reports increased 26.9% to 17,055: 15,529 DecisionDx-Melanoma and 1,526 DecisionDx-UM. Gross margin expanded with revenue growth and operating leverage.
Reported 2019 net income included a $5.2 million non-cash gain on extinguishment of convertible debt; therefore, it does not represent recurring operating earnings. Interest expense was $4.6 million, versus $2.3 million in 2018. Net income attributable to common stockholders was $3.0 million; reported diluted loss per share was $0.21, reflecting the accounting treatment of convertible notes. The company raised $65.9 million in net IPO proceeds.
In Q4 2019, revenue was $17.6 million and net income was $2.1 million, compared with Q4 2018 revenue of $11.4 million and net income of $3.9 million. Q4 2018 included $5.2 million of revenue recognized for prior-period tests after Medicare coverage and reimbursement were established.
Liquidity, debt and material changes
Year-end current assets were $116.7 million and current liabilities were $15.3 million. Operating cash flow improved by $19.3 million year over year, to a positive $7.0 million. Financing activities provided $88.3 million, chiefly from the IPO and convertible notes. Management stated that cash on hand and anticipated product collections should fund operations for the foreseeable future, while also expecting significant expenses and operating losses over the next two years as it invests in commercial and research activities.
Debt principal was $26.7 million at year-end, including $5.8 million classified as current. The secured term loan bears interest at 8.55% at year-end; principal repayments were scheduled to begin in June 2020, with maturity in November 2022. It is secured by substantially all assets other than intellectual property and includes revenue covenants and other restrictions. Amendments in February and March 2020 changed covenant testing and established 2020 revenue targets; the lenders also waived a deposit-account covenant default. The company reported compliance with the covenant at the most recently tested quarter.
Medicare, Medicare Advantage, UnitedHealthcare and BlueCross BlueShield plans accounted for 49%, 29%, 6% and 6% of 2019 revenue, respectively. Revenue includes estimates for variable consideration; the company recorded $2.5 million of positive adjustments related to prior-period tests in 2019. It had not recognized revenue on 2,698 disputed DecisionDx-Melanoma Medicare claims awaiting an administrative-law-judge decision.
Outlook, commentary and key risks
Management intended to launch DecisionDx-SCC and the suspicious pigmented lesion test in the second half of 2020, subject to clinical study progress and results. The filing gives no specific revenue or earnings guidance. Management planned continued commercial expansion, evidence generation and reimbursement efforts. In 2019, commercial and medical-affairs headcount expanded, and DecisionDx-Melanoma total ordering clinicians reached 3,927, up 32% year over year.
Key risks include dependence on reimbursement and a concentrated group of payors; uncertain commercial coverage and pricing; changes to Medicare rates under ADLT rules; unresolved legacy Medicare appeals; potential changes in FDA oversight of laboratory-developed tests; and execution, validation and reimbursement risks for pipeline products. The loan’s revenue covenant and collateral provisions constrain flexibility. The company also identified reliance on sole or limited suppliers, a single Phoenix laboratory, data-security and patient-sample risks, and competition from established diagnostic providers. Prior internal-control material weaknesses were reported as remediated at December 31, 2019; disclosure controls were assessed as effective. No material pending litigation was reported. The company did not expect to pay dividends.
Investor facts to verify
- Whether the 2020 pipeline launch plans were achieved and supported by final clinical validation and utility evidence.
- Actual reimbursement rates and coverage developments, including the Medicare ADLT rate-setting process and commercial payer adoption.
- The outcome and financial impact of the 2,698 consolidated Medicare appeals, and whether any related revenue was recognized.
- Revenue growth, test volumes, collections and cash generation relative to the company’s increased operating and research spending.
- Ongoing compliance with debt covenants, scheduled principal repayments and terms of the February and March 2020 amendments.
- Whether the reported remediation of internal-control weaknesses remained effective as the company scaled its operations.